Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core

• Main Authors: Daniil R. Bazanov (Author), Nikolay V. Pervushin (Author), Egor V. Savin (Author), Michael D. Tsymliakov (Author), Anita I. Maksutova (Author), Victoria Yu. Savitskaya (Author), Sergey E. Sosonyuk (Author), Yulia A. Gracheva (Author), Michael Yu. Seliverstov (Author), Natalia A. Lozinskaya (Author), Gelina S. Kopeina (Author)
• Format: Book
• Published: MDPI AG, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The use of p53-MDM2 inhibitors is a prospective strategy in anti-cancer therapy for tumors expressing wild type p53 protein. In this study, we have applied a simple approach of two-step synthesis of imidazoline-based alkoxyaryl compounds, which are able to efficiently inhibit p53-MDM2 protein-protei...